Pharmacologic treatment of gastroparesis: What is (still) on the horizon?

ElsevierVolume 72, October 2023, 102395Current Opinion in PharmacologyAuthor links open overlay panel, Abstract

Gastroparesis is a neuromuscular disorder of the upper gastrointestinal tract. Patients typically complain about early satiety, postprandial fullness, nausea and vomiting. Etiology is multifactorial. Treatment strategies include nutritional support, pharmacologic agents or surgery for refractory cases. Metoclopramide is the first and only FDA approved pharmacologic agent for (diabetic) Gastroparesis. A couple of compounds are currently in clinical testing. Some beacons of hope have failed recently, however. Here we present an update on possible future treatment options.

© 2023 The Authors. Published by Elsevier Ltd.

留言 (0)

沒有登入
gif